Investment Areas
Deciphering the entire human genome that consists of approximately 30,000 genes provides limitless opportunities to improve human health. Researchers in the field of regenerative medicine face a unique and complex set of challenges in their efforts to translate stem-cell science and gene-editing technology from research laboratories through clinical trials and ultimately to patients. Nature offers only a finite set of protein ligands to develop signaling molecules. One fundamental industry challenge is in chimera technology to overcome this barrier. JPC plays a pivotal role in breaking through the technological barrier by capturing the Three I's intellectual and financial investments.